BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36871347)

  • 1. Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature.
    Zafar A; Lim MY; Abou-Ismail MY
    Thromb Res; 2023 Apr; 224():73-79. PubMed ID: 36871347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
    Grall M; Daviet F; Chiche NJ; Provot F; Presne C; Coindre JP; Pouteil-Noble C; Karras A; Guerrot D; François A; Benhamou Y; Veyradier A; Frémeaux-Bacchi V; Coppo P; Grangé S
    BMC Nephrol; 2021 Jul; 22(1):267. PubMed ID: 34284729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
    Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
    Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
    Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
    Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
    Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
    Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case Report of Quinine-Induced Thrombotic Microangiopathy Successfully Treated With Eculizumab.
    Ng JY; Lenton D; Kerridge I; Wong C
    J Investig Med High Impact Case Rep; 2024; 12():23247096241235617. PubMed ID: 38477293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
    Øzbay LA
    Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of eculizumab in gemcitabine induced thrombotic microangiopathy.
    Krishnappa V; Gupta M; Shah H; Das A; Tanphaichitr N; Novak R; Raina R
    BMC Nephrol; 2018 Jan; 19(1):9. PubMed ID: 29329518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
    Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
    BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
    Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
    Front Immunol; 2020; 11():564647. PubMed ID: 33552043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
    Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.
    Gabr JB; Bilal H; Mirchia K; Perl A
    J Investig Med High Impact Case Rep; 2020; 8():2324709620947266. PubMed ID: 32757799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.